Insmed, Inc. (NASDAQ:INSM) Receives Consensus Recommendation of "Buy" from Brokerages

Key Points

• Insmed has an average analyst rating of Buy from 25 firms (22 buy, 2 strong buy, 1 sell) with an average 12‑month price target of $213.23.
• Company insiders have been net sellers — the COO sold 88,060 shares and the CEO sold 10,699 shares, with insiders offloading a total of 179,777 shares worth $28.25M over the last quarter.
• Financially, revenue rose 152.6% year‑over‑year to $263.84M, but Insmed missed EPS estimates with (−$1.54) and remains unprofitable with negative net margin and ROE.

Insmed, Inc. (NASDAQ:INSM - Get Free Report) has been assigned an average rating of "Buy" from the twenty-five research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, twenty-two have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $213.2273.

A number of equities analysts recently commented on INSM shares. Bank of America boosted their price target on shares of Insmed from $211.00 to $213.00 and gave the company a "buy" rating in a research report on Tuesday, March 24th. Raymond James Financial began coverage on Insmed in a research report on Friday, April 10th. They set an "outperform" rating and a $200.00 price objective on the stock. Stifel Nicolaus upped their target price on Insmed from $205.00 to $208.00 and gave the stock a "buy" rating in a report on Tuesday, March 24th. Barclays increased their target price on Insmed from $231.00 to $237.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 1st. Finally, Guggenheim restated a "buy" rating and issued a $230.00 target price on shares of Insmed in a research note on Thursday, April 16th.

Insiders Place Their Bets

In other news, COO Roger Adsett sold 88,060 shares of Insmed stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total value of $14,497,317.80. Following the completion of the transaction, the chief operating officer owned 106,810 shares of the company's stock, valued at $17,584,130.30. The trade was a 45.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO William Lewis sold 10,699 shares of the stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $143.97, for a total transaction of $1,540,335.03. Following the sale, the chief executive officer directly owned 301,185 shares in the company, valued at $43,361,604.45. This trade represents a 3.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 179,777 shares of company stock worth $28,252,720. 2.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. IFM Investors Pty Ltd boosted its stake in shares of Insmed by 6.4% in the 1st quarter. IFM Investors Pty Ltd now owns 42,740 shares of the biopharmaceutical company's stock worth $6,989,000 after buying an additional 2,575 shares during the last quarter. iA Global Asset Management Inc. raised its position in Insmed by 31.1% in the first quarter. iA Global Asset Management Inc. now owns 34,977 shares of the biopharmaceutical company's stock worth $5,719,000 after acquiring an additional 8,295 shares during the period. Lansforsakringar Fondforvaltning AB publ bought a new position in Insmed in the first quarter worth approximately $11,199,000. Janney Montgomery Scott LLC increased its position in Insmed by 17.5% in the first quarter. Janney Montgomery Scott LLC now owns 3,276 shares of the biopharmaceutical company's stock worth $536,000 after buying an additional 488 shares in the last quarter. Finally, Pictet Asset Management Holding SA raised its stake in shares of Insmed by 14.9% in the first quarter. Pictet Asset Management Holding SA now owns 1,102,248 shares of the biopharmaceutical company's stock worth $178,659,000 after buying an additional 143,285 shares during the period.

Insmed Price Performance

INSM stock opened at $135.17 on Monday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The firm has a market cap of $29.18 billion, a P/E ratio of -21.09 and a beta of 1.10. The firm's fifty day moving average is $149.27 and its 200 day moving average is $167.01. Insmed has a 52 week low of $63.81 and a 52 week high of $212.75.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The firm had revenue of $263.84 million during the quarter, compared to the consensus estimate of $263.97 million. During the same quarter in the prior year, the business posted ($1.32) EPS. The firm's revenue for the quarter was up 152.6% on a year-over-year basis. Research analysts predict that Insmed will post -2.51 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.